Submission of Outcome of Board Meeting.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Astal Laboratories Limited's board met on February 14, 2026 and approved the unaudited standalone financial results for Q3 FY26 (quarter ended December 31, 2025). Total revenue for the quarter stood at Rs. 5,227.18 lakhs, a sharp jump from Rs. 1,451.47 lakhs in the same quarter last year and Rs. 3,754.91 lakhs in the preceding quarter (Q2 FY26). Net profit for the quarter was Rs. 235.73 lakhs versus Rs. 244.46 lakhs in Q3 FY25, while 9-month FY26 profit reached Rs. 702.96 lakhs compared to Rs. 618.05 lakhs in the same period last year. Basic EPS for Q3 stood at Rs. 2.19 and Rs. 6.82 for the 9-month period. The company operates solely in the Pharmaceutical Ingredients (Bulk Drugs) segment.
Massive year-on-year revenue growth of roughly 260% signals major business expansion, likely tied to the company's recent rebranding from Macro International Limited. However, a slight dip in quarterly profit versus the year-ago quarter and a sequential profit decline from Q2 may modestly temper near-term investor enthusiasm.